The SCOUT-Echo-AI study is designed to evaluate the real-world impact of AI-enabled opportunistic liver disease screening. Steatotic liver disease (SLD) is frequently observed in individuals with cardiovascular disease, and often goes undiagnosed until advanced liver conditions such as fibrotic liver disease and hepatocellular carcinoma have developed. Routine transthoracic echocardiography captures subcostal liver views, which are currently not routinely utilized clinically. The EchoNet-Liver algorithm, utilizing artificial intelligence (AI), is employed to predict the presence of liver disease based on these echocardiograms. The study will involve an estimated enrollment of approximately 3,000 patients across six diverse U.S. healthcare systems: Kaiser Permanente Northern California, Stanford Healthcare, Cedars-Sinai Medical Center, University of California Los Angeles, Northwestern Medicine, and Massachusetts General Brigham. Participants will undergo routine echocardiograms, and the AI algorithm will analyze these images. Clinicians or participants will be notified of potential undiagnosed liver disease, triggering site-specific workflows for confirmation of the findings. The primary outcomes will measure the detection rates of SLD and fibrotic liver disease, alongside the positive predictive values within 12 months of the AI identification. Secondary outcomes will assess diagnostic accuracy relative to other gold-standard modalities, treatment initiation timelines, time to diagnosis, and the impact on other clinical events. Comparisons will be made against historical usual-care and contemporary below-threshold cohorts. The study’s design is a single-arm, prospective, multicenter, open-label pragmatic interventional trial. The goal is to understand the clinical utility and impact of AI-enabled opportunistic liver disease screening.